XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Home
Menu

Lung Trials

A list of our early phase Lung Cancer trials which are open to recruitment at University College London Hospitals

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

Additional early phase clinical trials recruiting Lung cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.

 

APL-101-01

Safety and efficacy of APL-101 in NSCLC and advanced solid tumors:  Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Local Project Reference:129619
Principal Investigator:Dr. Martin Forster
Drug Class/ Treatment:APL-101 (C-Met Inhibitor)
Patient Population:Non-Small Cell Lung Cancer (NSCLC)
Trial Hosted By - UCLH Clinical Research Facility (CRF)

FURMO 002

A PHASE 1b DOSE ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF FURMONERTINIB IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH ACTIVATING EGFR OR HER2 MUTATIONS, INCLUDING EXON 20 INSERTION MUTATIONS

Local Project Reference:150619
Principal Investigator:Dr Martin Forster
Drug Class/Treatment:

Furmonertinib (EGFR Tyrosine-Kinase Inhibitor)

Patient Population:Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutations (Including Exon 20 Insertion Mutations)
Trial Hosted By - UCLH Clinical Research Facility (CRF)

 

ATX-NS-001 (CHIRON)

ATX-NS-001 - ATL001 for the Treatment of Non-Small Cell Lung Cancer:  An open label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neo-antigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON)

Local Project Reference:18/0540
Principal Investigator:Dr. Martin Forster
Drug Class/ Treatment:ATL001 - Autologous Clonal Neoantigen Reactive T-Cell (cNeT)
Patient Population:Non-Small Cell Lung Cancer (NSCLC)
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

PALOMA-2

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer

Local Project Reference:1006215
Principal Investigator:Dr Sarah Benafif
Drug Class/ Treatment:

Amivantamab (Bi-specific EGF & MET Receptor-Directed Antibody)

Subcutaneous

Patient Population:

Non-Small Cell Lung Cancer (NSCLC):

  • Cohorts 1, 3, 5, and 6 - EGFR Exon19del or Exon 21 L858R mutation
  • Cohort 2 - EGFR Exon20ins mutation
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

CONCORDE

A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer

Local Project Reference:118073
Principal Investigator:Dr. Crispin Hiley
Drug Class/ Treatment:

Radiotherapy + Olaparib (PARP Inhibitor) or AZD1390 (Oral ATM Inhibitor)

Patient Population:Non-Small Cell Lung Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

 

 

 

 

 

 

On-hold to recruitment

METalmark (Kaleidoscope)
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Local Project Reference:152527
Principal Investigator:Dr Sarah Benafif
Drug Class/ Treatment:Amivantamab (Bi-Specific Antibody) + Capmatinib (C-Met RTK)Phase II Dose Expansion
Patient Population:

Non-Small Cell Lung Cancer (NSCLC)

  • Met Exon 14 Skipping Mutation Treatment Naive
  • Met Exon 14 Skipping Mutation, Prior Therapy
  • Met Amplification, Prior Therapy
Trial Hosted By - UCLH Clinical Research Facility (CRF)